Ultraearly Intravenous Thrombolysis for Acute Ischemic Stroke in Mobile Stroke Unit and Hospital Settings
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29986934
DOI
10.1161/strokeaha.118.021536
PII: STROKEAHA.118.021536
Knihovny.cz E-zdroje
- Klíčová slova
- intracranial hemorrhages, reperfusion, stroke, acute, thrombolytic therapy,
- MeSH
- čas zasáhnout při rozvinutí nemoci * trendy MeSH
- cévní mozková příhoda diagnóza farmakoterapie MeSH
- hospitalizace * trendy MeSH
- intravenózní podání MeSH
- ischemie mozku diagnóza farmakoterapie MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mobilní zdravotnické jednotky * MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- trombolytická terapie metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Background and Purpose- Mobile stroke units (MSUs) are known to increase the proportion of acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT) in the first golden hour (GH) after onset compared with hospital settings (HS). However, because of the low number of AIS patients treated with intravenous thrombolysis within this ultraearly time window in conventional care, characteristics, and outcome of this subgroup of AIS patients have not been compared between MSU and HS. Methods- MSU-GH patients were selected from the Berlin-based MSU (STEMO [Stroke Emergency Mobile]), whereas HS-GH patients were selected from the SITS-EAST (Safe Implementation of Treatments in Stroke-East) registry. The outcome events of interest included the rates of favorable functional outcome (modified Rankin Scale scores of 0 or 1), distribution of the modified Rankin Scale scores, and mortality after 3 months between MSU-GH and HS-GH groups. Results- We identified 117 MSU-GH (38.4% of 305 MSU-treated patients) and 136 HS-GH (0.9% of 15 591 HS-treated patients) eligible patients without prestroke disability. No significant differences were documented in the rates of favorable functional outcome (51.3% versus 46.2%, P=0.487) and mortality (7.7% versus 9.9%, P=0.576) at 3 months, or in the distribution of 3-month modified Rankin Scale scores between the 2 groups ( P=0.196). In multivariable logistic regression analyses, adjusting for potential confounders, MSU treatment was not associated with a significantly different likelihood of favorable functional outcome (odds ratio, 1.84 for MSU patients; 95% CI, 0.86-3.96) or mortality (odds ratio, 0.95; 95% CI, 0.28-3.20) at 3 months. Conclusions- There is no evidence that safety and efficacy of ultraearly intravenous thrombolysis for AIS differs when used in MSUs or in HS.
Center for Stroke Research Berlin Charité Universitätsmedizin Berlin Germany
Department of Neurology and Neurosurgery University of Tartu Estonia
Department of Neurology Charité Universitätsmedizin Berlin Germany
Department of Neurology Unfallkrankenhaus Berlin Germany
Department of Neurology University of Ioannina School of Medicine Greece
Department of Neurology University of Tennessee Health Science Center Memphis
Citace poskytuje Crossref.org